

Sarborg Acquires Portfolio of Next-Generation Patented Cannabinoid Solid-Form Assets

WILMINGTON, De -- April 28, 2026 -- Sarborg Limited (“Sarborg” or the “Company”), today announced that it has completed the acquisition of a portfolio of solid-form cannabinoid assets (the “Assets”) from Manoira Corporation (“Manoira”).

The transaction comprises four solid-form and cocrystal cannabinoid assets, including CBDA, THCA, CBG and CBDA Choline. Three of the Assets are protected by granted patents (12319649, 17/999,315 and 17/640,822), with CBDA Choline expected to be granted shortly.

Total consideration for the transaction was \$65 million, satisfied through the issuance of new ordinary shares in Sarborg, representing 10% of the Company’s issued share capital on a fully diluted basis immediately following completion.

The acquired Assets represent a new generation of cannabinoid-based formulations, offering enhanced physicochemical properties compared to traditional forms, including improvements in stability, purity and dosing consistency. These characteristics are expected to support the development of more reliable and scalable pharmaceutical and consumer applications.

Sarborg believes that the acquisition significantly strengthens its intellectual property portfolio within the cannabinoid sector, providing access to differentiated, patent-protected formulations across large and rapidly evolving markets. The Company intends to leverage its proprietary Signature Intelligence to further analyse these Assets, identify high-potential disease indications, and support downstream partnering and commercialization strategies.

In addition to their core pharmaceutical applications, the solid-form nature of the Assets enables greater flexibility in formulation and delivery, supporting the development of next-generation cannabinoid products with improved performance characteristics relative to existing market offerings.

The acquisition is aligned with Sarborg’s broader strategy of acquiring and developing high-value, IP-protected assets which can be enhanced through data-driven insight and positioned for commercialisation through strategic partnerships.

“This acquisition represents a significant step in the expansion of our intellectual property portfolio into high-value cannabinoid markets,” said Mark Taylor, Director of Sarborg. “These assets provide a strong foundation of patent-protected, next-generation formulations which we believe are well positioned for both pharmaceutical and commercial development. By applying our Signature Intelligence to these compounds, we expect to further enhance their value through targeted indication selection and partnership strategies.”

About Sarborg Limited

Sarborg is an agentic AI signature intelligence business, built on the principle that signatures can function as a universal data language to identify, interpret, and generate high-value opportunities across multiple sectors. By analysing, matching, and learning from biological, chemical, and industrial signatures, Sarborg’s agents create a continuously evolving network of intelligence-driven insights.

Investors & Media:

info@sarborg.com

www.sarborg.com